0001826834-22-000002.txt : 20220318 0001826834-22-000002.hdr.sgml : 20220318 20220318141306 ACCESSION NUMBER: 0001826834-22-000002 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20220318 DATE AS OF CHANGE: 20220318 EFFECTIVENESS DATE: 20220318 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Biopharmaceutical Research Co CENTRAL INDEX KEY: 0001826834 IRS NUMBER: 820650107 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-434007 FILM NUMBER: 22752024 BUSINESS ADDRESS: STREET 1: 11045 COMMERCIAL PARKWAY CITY: CASTROVILLE STATE: CA ZIP: 95012 BUSINESS PHONE: 831-632-0913 MAIL ADDRESS: STREET 1: 11045 COMMERCIAL PARKWAY CITY: CASTROVILLE STATE: CA ZIP: 95012 D/A 1 primary_doc.xml X0708 D/A LIVE 0001826834 Biopharmaceutical Research Co 11045 COMMERCIAL PARKWAY CASTROVILLE CA CALIFORNIA 95012 831-632-0913 DELAWARE Biopharmaceutical Research Company, LLC None Corporation true 2017 George Hodgin 11045 Commercial Parkway Castroville CA CALIFORNIA 95012 Executive Officer Director Charles Schumacher 11045 Commercial Parkway Castroville CA CALIFORNIA 95012 Director Other Technology Decline to Disclose 06b true 0000925421-22-000002 2022-02-08 false true true true false 0 North Point Mergers and Acquisitions, Inc. 133300 None None 580 California Street, Suite 200 San Francisco CA CALIFORNIA 94104 CA CALIFORNIA CT CONNECTICUT KS KANSAS LA LOUISIANA MA MASSACHUSETTS NJ NEW JERSEY NY NEW YORK NC NORTH CAROLINA TN TENNESSEE TX TEXAS false 5000000 2535500 2464500 false 22 152130 true 0 North Point Mergers and Acquisitions, Inc. will receive equity private placement fees corresponding to (i) a cash fee of 6% of the total investments and (ii) warrants representing 3% of the total investments. 0 false Biopharmaceutical Research Co /s/ George Hodgin George Hodgin Chief Executive Officer 2022-03-18